Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142051 · ClinicalTrials.gov registry record · Phase 2
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
A Phase 2 study, sponsored by Boston Children's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00142051 is a Phase 2 study that was terminated before completion, run by Boston Children's Hospital. The registered enrollment target is 18 participants.
The verdict
NCT00142051, a Phase 2 study, was terminated before completion, sponsored by Boston Children's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Randomized, double blind placebo controlled clinical trial to evaluate effectiveness and safety of inhaled nitric oxide for the treatment of sickle cell painful crisis in pediatric patients with sickle cell disease.
Interventions
- DRUG nitric oxide
- DRUG oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142051
The ClinicalTrials.gov registry entry for NCT00142051 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nitric oxide is the first listed.
NCT00142051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142051 about?
NCT00142051 is a clinical study titled "Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis". Randomized, double blind placebo controlled clinical trial to evaluate effectiveness and safety of inhaled nitric oxide for the treatment of sickle cell painful crisis in pediatric patients with sickle cell disease.
What is the current status of trial NCT00142051?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00142051?
The interventions under investigation include: nitric oxide (DRUG), oxygen (DRUG).
Who is sponsoring clinical trial NCT00142051?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.